NexBio Initiates Phase II Trial Of DAS181 (Fludase(R)) For Treatment Of Influenza, Including Pandemic Influenza A(H1N1)

NexBio, Inc. announced the initiation of a double blind placebo controlled multi-center trial in the U.S. and Mexico of DAS181 (Fludase®) for the treatment of laboratory confirmed influenza infection. DAS181 is an investigational host-targeted drug candidate that blocks entry of influenza virus into cells of the respiratory tract…